MoonLake Immunotherapeutics MLTX Change in Lease Liabilities
Change in Lease Liabilities at other companies
Other financials
Where this comes from
Reported directly by MoonLake Immunotherapeutics in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOperatingLeaseLiability.
The official record: MoonLake Immunotherapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about MoonLake Immunotherapeutics's change in lease liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is MoonLake Immunotherapeutics's change in lease liabilities?
- MoonLake Immunotherapeutics (MLTX) reported change in lease liabilities of -$389K in Q1 2026.
- How has MoonLake Immunotherapeutics's change in lease liabilities changed year-over-year?
- MoonLake Immunotherapeutics's change in lease liabilities decreased by 52.5% year-over-year, from -$255K to -$389K.
- What is the long-term trend for MoonLake Immunotherapeutics's change in lease liabilities?
- Over 3 years (2022 to 2025), MoonLake Immunotherapeutics's change in lease liabilities has grown at a 100.1% compound annual growth rate (CAGR), from -$152.43K to -$1.22M.
- What does change in lease liabilities mean?
- Cash payments for operating leases reducing the lease liability, partially offset by new lease commencements.